Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $32.2 million.

  • GeneDx Holdings' Cost of Revenue rose 1091.75% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year increase of 1274.27%. This contributed to the annual value of $111.1 million for FY2024, which is 133.88% down from last year.
  • Latest data reveals that GeneDx Holdings reported Cost of Revenue of $32.2 million as of Q3 2025, which was up 1091.75% from $31.8 million recorded in Q2 2025.
  • GeneDx Holdings' Cost of Revenue's 5-year high stood at $77.7 million during Q4 2022, with a 5-year trough of $25.0 million in Q1 2024.
  • Moreover, its 5-year median value for Cost of Revenue was $31.8 million (2025), whereas its average is $42.4 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 5133.44% in 2021, then plummeted by 6567.28% in 2023.
  • Over the past 5 years, GeneDx Holdings' Cost of Revenue (Quarter) stood at $60.6 million in 2021, then increased by 28.16% to $77.7 million in 2022, then crashed by 65.67% to $26.7 million in 2023, then grew by 10.39% to $29.4 million in 2024, then grew by 9.45% to $32.2 million in 2025.
  • Its Cost of Revenue was $32.2 million in Q3 2025, compared to $31.8 million in Q2 2025 and $28.6 million in Q1 2025.